Cargando…

Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models

RATIONALE & OBJECTIVE: Early prediction of chronic kidney disease (CKD) progression to end-stage kidney disease (ESKD) currently use Cox models including baseline estimated glomerular filtration rate (eGFR) only. Alternative approaches include a Cox model that includes eGFR slope determined over...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Brand, Jan A. J. G., Dijkstra, Tjeerd M. H., Wetzels, Jack, Stengel, Bénédicte, Metzger, Marie, Blankestijn, Peter J., Lambers Heerspink, Hiddo J., Gansevoort, Ron T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508737/ https://www.ncbi.nlm.nih.gov/pubmed/31071186 http://dx.doi.org/10.1371/journal.pone.0216559

Ejemplares similares

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Worldwide Disparity in the Relation Between CKD Prevalence and Kidney Failure Risk
por: van Rijn, Marieke H.C., et al.
Publicado: (2020)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney disease
por: Smeijer, J. David, et al.
Publicado: (2023)

Monitoring Kidney Function and Albuminuria in Patients With Diabetes
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Intra-individual variability of eGFR trajectories in early diabetic kidney disease and lack of performance of prognostic biomarkers
por: Kerschbaum, Julia, et al.
Publicado: (2020)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
por: Vart, Priya, et al.
Publicado: (2022)

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
por: Heerspink, Hiddo J L
Publicado: (2019)

Differences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care
por: Peeters, Mieke J, et al.
Publicado: (2012)

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease
por: Heerspink, Hiddo J. L., et al.
Publicado: (2016)

Uremic Solutes in Chronic Kidney Disease and Their Role in Progression
por: van den Brand, Jan A. J. G., et al.
Publicado: (2016)

Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?
por: Chung, Edmund Y. M., et al.
Publicado: (2022)

Proteomics for prediction of disease progression and response to therapy in diabetic kidney disease
por: Pena, Michelle J., et al.
Publicado: (2016)

Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2021)

Longitudinal uric acid has nonlinear association with kidney failure and mortality in chronic kidney disease
por: Prezelin-Reydit, Mathilde, et al.
Publicado: (2023)

Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges
por: Tye, Sok Cin, et al.
Publicado: (2022)

Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes
por: Hellemons, Merel E., et al.
Publicado: (2012)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study
por: Meems, Laura M. G., et al.
Publicado: (2016)

Fibroblast growth factor 23 but not copeptin is independently associated with kidney failure and mortality in patients with chronic kidney disease
por: Michon-Colin, Arthur, et al.
Publicado: (2023)

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers
por: Idzerda, Nienke M A, et al.
Publicado: (2019)

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?
por: Perco, Paul, et al.
Publicado: (2018)

Kidney Function Decline and Apparent Treatment-Resistant Hypertension in the Elderly
por: Kaboré, Jean, et al.
Publicado: (2016)

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
por: Mol, Peter G. M., et al.
Publicado: (2018)

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709
por: Lambers Heerspink, Hiddo J., et al.
Publicado: (2011)

Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression?
por: Boucquemont, Julie, et al.
Publicado: (2014)

Obesity-Related Kidney Disease: Current Understanding and Future Perspectives
por: Kreiner, Frederik F., et al.
Publicado: (2023)

The Geographical Distribution of Leadership in Globalized Clinical Trials
por: Hoekman, Jarno, et al.
Publicado: (2012)

How to measure and monitor albuminuria in healthy toddlers?
por: van den Belt, Sophie Marielle, et al.
Publicado: (2018)

Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Machine‐learning–based early prediction of end‐stage renal disease in patients with diabetic kidney disease using clinical trials data
por: Belur Nagaraj, Sunil, et al.
Publicado: (2020)

Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort
por: Vervloet, Marc G, et al.
Publicado: (2012)

Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years
por: Lawson, Claire A, et al.
Publicado: (2021)

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers
por: Tye, Sok Cin, et al.
Publicado: (2022)

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Koomen, Jeroen V., et al.
Publicado: (2021)

Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease
por: Kaboré, Jean, et al.
Publicado: (2016)

Potential Surrogate Outcomes for Kidney Failure in Advanced CKD: Evaluation of Power and Predictive Ability in CKDopps
por: Zee, Jarcy, et al.
Publicado: (2021)

The Use of Surrogate Endpoints in Regulating Medicines for Cardio-Renal Disease: Opinions of Stakeholders
por: Schievink, Bauke, et al.
Publicado: (2014)

Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
por: Dekkers, Claire C J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cst49ck8n5ilj6n7sdargjj3qp